Improving Clinic Capacity with Faricimab

This infographic is funded and developed by Hoffmann-La Roche Ltd.
Prescribing information and adverse event reporting information can be found at the bottom of this infographic.

Faricimab

The first intraocular bispecific antibody[1–9]

SUSTAINED VISUAL GAINS

REDUCTION IN RETINAL FLUID



FAVOURABLE BENEFIT-RISK PROFILE
with low rates of ocular adverse events

REAL-WORLD EVIDENCE
that aligns with clinical trial data

STRONG DURABILITY
with extended treatment intervals

Faricimab optimises clinic capacity and leads to:[10–15]

Reduction
in Saturday clinics*[15]

More time
during appointments for personalised care[15]

Improved **cost-effectiveness**
of treatment[16]

With faricimab:[15]

1. REDUCED WAITING TIMES
2. REDUCED TREATMENT BURDEN
3. REDUCED SERVICE COSTS

CLICK TO LEARN MORE

*In a prospective audit of the real-world effectiveness and safety of faricimab conducted at the Manchester Royal Eye Hospital, the introduction of faricimab resulting in the freeing up of clinic capacity, which led to a 75% reduction in the number of Saturday clinics, from 3–4 per month to 1 per month.

1. Panos GD et al. Drug Des Devel Ther 2023;17:2861–73; 2. Genentech. Genentech's Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study. 2024. Available at: https://www.gene.com/media/press-releases/15041/2024-10-18/genentechs-vabysmo-improved-vision-in-un. Last accessed: 21st January 2025; 3. Wong TY et al. Ophthalmology 2024;131(6):708–23; 4. Khanani AM et al. Ophthalmology 2024:131(8):914–26; 5. Khanani AM et al. Faricimab in nAMD and DME: Latest Updates. Angiogenesis, Exudation and Degeneration Conference, 10th–11th February, 2023; 6. Koh AHC et al. Extended Treatment Outcomes and the Potential for Q20W Dosing With Faricimab in Neovascular Age-Related Macular Degeneration: a Post Hoc Analysis of the Pivotal TENAYA/LUCERNE Trials. Asia-Pacific Vitreo-Retina Society Congress, 8th–10th December, 2023; 7. Lim JI et al. Anti-VEGF/Anti–Ang-2 Year 2 Outcomes for Diabetic Macular Edema and Neovascular AMD. American Academy of Ophthalmology Retina Subspecialty Day, 30th September – 3rd October, 2022; 8. Singh R. Real-World Outcomes in Faricimab Treatment for Neovascular AMD and DME. Brazilian Retina and Vitreous Society Congress, 18th–21st April, 2024; 9. Borkar D et al. Real-World Clinical and Anatomical Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab: The FARETINA-DME Study. Abstract 6241. ARVO Annual Meeting, 5th–9th May, 2024; 10. Cassels N, Chhabra R, et al. Real world experience of Faricimab for treatment of neovascular age-related macular degeneration when switched from an alternative anti-VEGF therapy, in a single UK tertiary centre. Abstract CA24-2667-7651. Euretina Congress, 19th–22nd September, 2024; 11. Cassels N, Chhabra R, et al. Real-world efficacy outcomes with intravitreal Faricimab in treatment naive neovascular Age-related Macular Degeneration patients over a 12 month period: experience from a large tertiary centre in the north west of England. Abstract CA24-2733-7651. Euretina Congress, 19th–22nd September, 2024; 12. Narayan A, Watson S-L. Faricimab: The solution to Treatment-Resistant Neovascular Age-related Macular Degeneration? A real-world long-term study. Abstract CA24-2447-249. Euretina Congress, 19th–22nd September, 2024; 13. Kashani S, Millar H. A review of the visual and structural outcome of patients with neovascular age-related macular degeneration (nAMD) after switching treatment to Faricimab (Vabysmo). Abstract CA24-2164-5982. Euretina Congress, 19th–22nd September, 2024; 14. Abdalla S et al. Acta Ophthalmol 2024;DOI:10.1111/aos.16774; 15. EMJ Innov 2025;9[Suppl 1]:2-11; 16. Li T et al. Ophthalmol Ther 2024;13(10):2577–97.

Vabysmo▼ (faricimab) 120 g/mL solution for injection is indicated for the treatment of adult patients with neovascular age-related macular degeneration (nAMD), visual impairment due to diabetic macular edema (DME), and visual impairment due to macular edema secondary to retinal vein occlusion (RVO).
Prescribing information for faricimab can be found here.
▼ This medicinal product is subject to additional monitoring in EU countries. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please report adverse reactions via the medinfo.roche.com website or via your national reporting system.
M-XX-00019699 | Date of preparation: February 2025

Roche